Clinical Trial Results:
A Phase III randomized, double-blind, placebo-controlled, parallel-group, group-sequential study to evaluate efficacy, safety and tolerability of BI 767551 for post-exposure prevention of SARS-CoV-2 infection in household contacts to a confirmed SARS-CoV-2 infected individual
Summary
|
|
EudraCT number |
2021-000408-39 |
Trial protocol |
BE |
Global completion date |
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
18 Aug 2021
|
First version publication date |
18 Aug 2021
|
Other versions |
|
Summary report(s) |
Statement |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.